Diclofenac is used to reduce pain, swelling, and inflammation from conditions like arthritis, menstrual cramps, and minor injuries. It works by reducing pain signals and decreasing inflammation in the body.[2] Voltaren is currently approved and in use across 54 indications[4].[1]
Voltaren is one of 928 small molecule programs targeting Low back pain. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
2828 competitors in Breast Cancer
Voltaren
Tykerb
Adriamycin
Avastin
Nolvadex
Prolia
Gemzar
MS Contin
Lexiscan
Adenocard
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jul 28, 1988
VOLTAREN
NDA NDA019201
Mar 28, 1991
VOLTAREN
NDA NDA020037
Nov 24, 1993
CATAFLAM
NDA NDA020142
Mar 8, 1996
VOLTAREN-XR
NDA NDA020254
May 4, 1998
DICLOFENAC SODIUM
NDA NDA020809
Oct 16, 2000
SOLARAZE
NDA NDA021005
Oct 17, 2007
VOLTAREN ARTHRITIS PAIN
NDA NDA022122
Jun 16, 2009
ZIPSOR
NDA NDA022202
Jun 17, 2009
CAMBIA
NDA NDA022165
Nov 4, 2009
PENNSAID
NDA NDA020947
Oct 18, 2013
ZORVOLEX
NDA NDA204592
Jan 16, 2014
PENNSAID
NDA NDA204623
Dec 23, 2014
DYLOJECT
NDA NDA022396
Sources
Details
Patent Cliff
Mar 22, 2027
Earliest patent expiration — generic entry possible after this date